Table I.
Analysis of clinical and biochemical indices in each group.
| Variable | NC | T2DM | LLI-LM | LLI-S |
|---|---|---|---|---|
| Number (M/F) | 60 (32/28) | 60 (30/30) | 70 (40/30) | 69 (38/31) |
| Age (years) | 51.0±10.20 | 52.3±7.86 | 60.5±8.53a,b | 60.8±8.2a,b |
| BMI (kg/m2) | 22.32±1.73 | 23.68±2.03a | 24.75±3.13a | 26.42±3.51a,b |
| WC (cm) | 74.13±6.25 | 83.9±11.29a | 87.1±7.89a | 91.08±9.67a–c |
| WHR | 0.80±0.07 | 0.85±0.09a | 0.89±0.05a | 0.91±0.05a,b |
| SBP (mmHg) | 116±15 | 121±20 | 135±17a,b | 145±25a–c |
| DBP (mmHg) | 72±7 | 78±16a | 83±11a,b | 85±12a,b |
| FPG (mmol/l) | 5.18±1.59 | 8.13±2.23a | 8.26±2.81a | 8.34±2.63a |
| FINS (mU/l) | 6.85±2.58 | 9.12±4.32a | 10.35±4.12a,b | 10.40±4.43a,b |
| HOMA-IR | 1.57±1.86 | 3.16±2.03a | 3.80±2.12a,b | 3.85±1.96a,b |
| HbA1c (%) | 5.09±0.41 | 7.71±1.63a | 8.25±2.11a | 8.66±1.78a |
| TC (mmol/l) | 4.61±1.13 | 4.68±1.01 | 4.82±1.2 | 4.92±1.36 |
| TG | 1.39±1.40 | 1.43±1.23 | 1.51±1.19 | 1.59±1.53 |
| HDL-C (mmol/l) | 1.16±0.34 | 1.12±0.25a | 1.10±0.21a | 1.05±0.31a |
| LDL-C (mmol/l) | 2.28±0.67 | 2.43±0.81 | 2.85±0.75a,b | 2.65±0.82a,b |
| Cystatin C (mg/l) | 0.76±0.26 | 0.78±0.39 | 1.07±0.53a,b | 1.55±0.78a–c |
Data expressed as the mean ± standard deviation.
a
P<0.05 vs. the NC group
b
P<0.05 vs. the T2DM group
c
P<0.05 vs. the LLI-LM group. NC, negative control; T2DM, type II diabetes mellitus; LLI-LM, low to moderate lower limb ischemia; LLI-S, severe lower limb ischemia; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin Alc; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.